S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NYSE:PFE - Pfizer Stock Price, Forecast & News

$32.67
+1.77 (+5.73 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$31.05
Now: $32.67
$32.85
50-Day Range
$28.49
MA: $34.16
$38.26
52-Week Range
$27.88
Now: $32.67
$44.56
Volume28.40 million shs
Average Volume45.55 million shs
Market Capitalization$181.24 billion
P/E Ratio11.38
Dividend Yield4.92%
Beta0.69
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Merck KGaA; licensing agreement with BionTech AG; and collaboration agreements with Merck & Co., Inc. and Eli Lilly & Company, as well as with Merck KGaA and Nektar Therapeutics to develop a therapy for treating pancreatic cancer. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More
Pfizer logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71708110
Phone212-733-2323

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.75 billion
Cash Flow$4.34 per share
Book Value$11.46 per share

Profitability

Net Income$16.27 billion

Miscellaneous

Employees88,300
Outstanding Shares5,547,640,000
Market Cap$181.24 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.


Pfizer (NYSE:PFE) Frequently Asked Questions

How has Pfizer's stock been impacted by COVID-19 (Coronavirus)?

Pfizer's stock was trading at $32.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PFE stock has increased by 1.6% and is now trading at $32.67. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Pfizer?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Pfizer.

When is Pfizer's next earnings date?

Pfizer is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Pfizer.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings data on Tuesday, January, 28th. The biopharmaceutical company reported $0.55 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.57 by $0.02. The biopharmaceutical company earned $12.69 billion during the quarter, compared to the consensus estimate of $12.73 billion. Pfizer had a return on equity of 27.01% and a net margin of 31.44%. Pfizer's revenue was down 9.2% on a year-over-year basis. During the same quarter last year, the business posted $0.64 earnings per share. View Pfizer's earnings history.

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Monday, December 16th. Stockholders of record on Friday, January 31st will be given a dividend of $0.38 per share on Friday, March 6th. This represents a $1.52 dividend on an annualized basis and a yield of 4.65%. The ex-dividend date of this dividend is Thursday, January 30th. This is a boost from Pfizer's previous quarterly dividend of $0.36. View Pfizer's dividend history.

How will Pfizer's stock buyback program work?

Pfizer declared that its Board of Directors has initiated a stock buyback plan on Friday, December 14th 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy up to 3.8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's leadership believes its stock is undervalued.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY20 earnings guidance on Tuesday, January, 28th. The company provided earnings per share guidance of $2.82-$2.92 for the period, compared to the Thomson Reuters consensus estimate of $2.72. The company issued revenue guidance of $48.5-$50.5 billion, compared to the consensus revenue estimate of $47.44 billion.

What price target have analysts set for PFE?

12 analysts have issued 12 month target prices for Pfizer's shares. Their forecasts range from $36.00 to $53.00. On average, they expect Pfizer's stock price to reach $41.48 in the next twelve months. This suggests a possible upside of 27.0% from the stock's current price. View analysts' price targets for Pfizer.

Has Pfizer been receiving favorable news coverage?

News headlines about PFE stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pfizer earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutPfizer.

Are investors shorting Pfizer?

Pfizer saw a increase in short interest in March. As of March 13th, there was short interest totaling 59,077,400 shares, an increase of 10.1% from the February 27th total of 53,670,000 shares. Based on an average trading volume of 25,250,000 shares, the short-interest ratio is currently 2.3 days. Currently, 1.1% of the company's shares are sold short. View Pfizer's Current Options Chain.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), General Electric (GE), Bank of America (BAC), AbbVie (ABBV), Walt Disney (DIS) and Exxon Mobil (XOM).

Who are Pfizer's key executives?

Pfizer's management team includes the following people:
  • Mr. Ian C. Read, Exec. Chairman (Age 65)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
  • Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Who are Pfizer's major shareholders?

Pfizer's stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (5.27%), Capital World Investors (3.41%), Geode Capital Management LLC (1.61%), Bank of New York Mellon Corp (1.08%), Norges Bank (1.07%) and Massachusetts Financial Services Co. MA (0.94%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View institutional ownership trends for Pfizer.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Massachusetts Financial Services Co. MA, PGGM Investments, California Public Employees Retirement System, LSV Asset Management, CI Investments Inc., PNC Financial Services Group Inc., and KBC Group NV. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, and Frank A Damelio. View insider buying and selling activity for Pfizer.

Which major investors are buying Pfizer stock?

PFE stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Capital World Investors, Renaissance Technologies LLC, Marshall Wace North America L.P., Macquarie Group Ltd., Sanders Capital LLC, Bank of New York Mellon Corp, and FIL Ltd. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc, and Scott Gottlieb. View insider buying and selling activity for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $32.67.

How big of a company is Pfizer?

Pfizer has a market capitalization of $181.24 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis. Pfizer employs 88,300 workers across the globe. View additional information about Pfizer.

What is Pfizer's official website?

The official website for Pfizer is http://www.pfizer.com/.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  1,352 (Vote Outperform)
Underperform Votes:  985 (Vote Underperform)
Total Votes:  2,337
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel